Thrombocytopenia is always of concern when encountered in emergency settings. We report a case of a 29-year-old women in whom a unique constellation of hematological disorders occurred. The patient had been diagnosed with idiopathic immune thrombocytopenia (ITP) in 2007, with a history of several thrombocytopenic flares. She now presented with homonymous hemianopia accompanied by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) and was soon after diagnosed with a posterior stroke. Symptoms were more reminiscent of acquired thrombotic thrombocytopenic purpura (aTTP) rather than ITP. Immediate treatment with plasma exchange and caplacizumab curtailed MAHA, and progressive ischemic disease was averted. ADAMTS-13 testing confirmed the diagnosis of immune-mediated aTTP. Repeated testing for ITP, however, also showed IgG-loaded thrombocytes with the former known anti-GPIIb/IIIa specificity. Furthermore, autoimmune hemolytic anemia (AIHA) could be detected by direct antiglobulin test showing IgG and complement loading of the patient's erythrocytes. The autoimmune background of all three entities suggested an underlying systemic disease. Indeed, systemic lupus erythematosus (SLE) serology was strongly positive allowing for the diagnosis of SLE. ITP and AIHA as well as aTTP can be secondary to SLE, but emergence of all three disorders has not been reported at the same time., Competing Interests: The authors declare that there is no conflict of interest. Figure 1.MRI scan of the brain owing to left homonymous hemianopia. A: Diffusion-weighted magnetic resonance imaging (DWI) showing at least two acute non-embolic microangiopathic infarctions of the left cerebral hemisphere (arrows). B: DWI sequence showing an acute territorial infarction of the right posterior cerebral artery (arrows). C: FLAIR sequence of the brain confirming right-sided posterior infarction (arrows). D: MR angiography of the intracranial arteries showing a peripheral thrombosis of the right posterior cerebral artery (arrow). Table 1.Course of ADAMTS-13 activity, systemic lupus erythematosus autoantibodies, direct antiglobulin test, and MAIPA. 11.05.201113.04.202122.04.202128.04.202205.05.202112.05.202101.06.202101.07.202119.08.202109.09.202101.03.2022ADAMTS-13 activity (%; 50 – 110)2< 1< 14283239628299ADAMTS-13 Ab (U/mL; < 16)314056168158755ANA (titer)1 : 5,1201 : 5,1201 : 10,2401 : 2,5601 : 2,5601 : 2,5601 : 640dsDNA Ab (ELISA; U/mL; < 20.0)189.8189.3> 200137.396.398.474.9Coombs test (DAT) Anti-IgG++++– Anti-C3d+++–Thrombocyte-specific Ab (MAIPA) GP IIb/IIIa++– GP Ib/IX–+– GP Ia/IIa–––ADAMTS = A disintegrin and metalloprotease with thrombospondin-1-like domains; Ab = antibody; ANA = anti-nuclear antibody; dsDNA = double-stranded DNA; DAT = direct antiglobulin test; IgG = immunoglobulin G; C3d = complement 3d; MAIPA = monoclonal antibody immobilization of platelet antigens; GP = glycoprotein. Figure 2.Clinical course demonstrating four different phases of thrombocytopenia, underlying etiologies and chosen therapies. The clinical course of the patient could be grouped into four different phases dominated by thrombocytopenia: The first phase (light blue) represented her last idiopathic immune thrombocytopenia (ITP) flare in December 2020, resulting in romiplostim therapy due to refractory disease. At that timepoint, autoimmune hemolytic anemia (AIHA) as well as microangiopathic hemolytic anemia (MAHA) were not known to exist, but increased lactate dehydrogenase levels may point towards a missed hemolysis. The second phase started in April 2021 (orange) and was dominated by the newly diagnosed acquired thrombotic thrombocytopenic purpura (aTTP), introducing plasma exchange and caplacizumab as well as rituximab in the patients’ therapeutic regimen. The third thrombocytopenic phase (yellow) superimposed aTTP and was due to overt upper respiratory tract infection with blastic cells in peripheral blood smears. It was mainly resolved by antibiotic treatment and increased doses of prednisolone. The fourth phase (light green) reflected the phase of SLE diagnosis and treatment as well as aTTP follow-up with stable thrombocyte counts and resolved ITP, AIHA, and MAHA., (© Dustri-Verlag Dr. K. Feistle.)